Kawamura et al. identified point mutations of TP53 in two of 20 initial patients and in four relapsed patients with BCP-ALL expressing TCF3-PBX1 and suggested a possible relationship between TP53 mutation and disease progression in BCP-ALL patients with TCF3-PBX1 fusion 8. This evidence concerns the gene PBX1 and acute lymphoblastic leukemia.